PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	interleukin 6	Mus musculus	146-150	
20130243-5	2010	INCB018424 inhibited interleukin-6 signaling (50% inhibitory concentration [IC(50)] = 281nM), and proliferation of JAK2V617F(+) Ba/F3 cells (IC(50) = 127nM).	ruxolitinib	0-10	interleukin 6	Mus musculus	21-34	
22904308-4	2012	We show in this paper that, Ruxolitinib, a recently described selective inhibitor of JAKs, increases TNF, IL-6, and IL-12 secretion in mouse bone marrow-derived macrophages stimulated with LPS.	ruxolitinib	28-39	interleukin 6	Mus musculus	106-110	
21705340-5	2011	These IL6-independent clones were dependent on NF-kappaB activity for their survival and proliferation but were resistant to dexamethasone and INCB018424, a selective Janus kinase 1/2 inhibitor.	ruxolitinib	143-153	interleukin 6	Mus musculus	6-9	
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	9-20	interleukin 6	Mus musculus	125-129	
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	158-169	interleukin 6	Mus musculus	125-129